Crescent Biopharma | GlycoMimetics

About Crescent Biopharma | GlycoMimetics

Crescent Biopharma, Inc. (Nasdaq: CBIO) is a clinical-stage biotechnology company focused on advancing oncology therapeutics for patients with solid tumors, headquartered in Waltham, Massachusetts. The company traces its origins to GlycoMimetics, Inc., founded in 2003 by Rachel King and Dr. John Magnani and listed on Nasdaq under the ticker GLYC. GlycoMimetics built its pipeline around glycobiology, developing small molecule drugs targeting E-selectin, with lead candidate uproleselan (GMI-1271) receiving Breakthrough Therapy and Fast Track designations from the U.S. FDA for acute myeloid leukemia. In October 2024, GlycoMimetics entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics for solid tumors, with the combined company planning to operate under the Crescent Biopharma name. The merger closed and shares began trading on Nasdaq under the ticker CBIO on June 16, 2025, concurrent with the close of a $200 million private financing led by Fairmount, Venrock Healthcare Capital Partners, BVF Partners, and a broad syndicate of healthcare-focused investors. Business Wire + 2 The combined company is led by CEO Joshua Brumm, who joined in March 2025, alongside Jonathan McNeill, M.D. as President and COO, Ellie Im, M.D. as Chief Medical Officer, and Rick Scalzo as CFO. Crescent's pipeline centers on CR-001, a tetravalent bispecific antibody combining blockade of PD-1 and VEGF, currently in the global Phase 1/2 ASCEND trial, alongside ADC programs CR-002 (PD-L1-targeted) and CR-003 (ITGB6-targeted). In December 2025, Crescent announced an exclusive partnership with Sichuan Kelun-Biotech and a further $185 million private placement to accelerate its combination therapy strategy, positioning CR-001 as a potential immuno-oncology backbone. Crescent Biopharma + 2 Keywords: GlycoMimetics, glycobiology, uproleselan, E-selectin antagonist, acute myeloid leukemia, PD-1 x VEGF bispecific antibody, antibody-drug conjugate, CR-001, CR-002, CR-003, solid tumors, immuno-oncology, Kelun-Biotech, clinical-stage biotechnology